SARS Cov_2 Incidence of Healthy Health Workers

Not Applicable

Completed

• Conditions: SARS COV-2 IgG Levels on Health Workers
• Interventions: Diagnostic Test: Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2

• Registration Number: NCT04845880
• Lead Sponsor: Baskent University

Brief Summary

Since the severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) first emerged in Wuhan, China, on 12 December 2019, it has spread rapidly across the world and developed into a pandemic. The pandemic has affected over 100 countries and regions, with over 132 million confirmed cases of COVID-19. The rapid spread of SARS-CoV-2 has caused considerable harm to public health and the economy. Alongside other laboratory tests and clinical findings of the COVID-19 infection, serological testing may be beneficial for epidemiological monitoring and outbreak control. The determination of antibodies enables confirmation of the SARS-CoV-2 infection in asymptomatic patients in addition to those with typical symptoms. In this study, we aimed to determine the SARS-CoV-2 seroprevalence and the IgG antibody levels among healthcare workers who frequently encountered COVID-19 patients in our hospital.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-10-01
• Primary Completion: 2021-03-01
• Status Verified: 2021-04
• Study Completion: 2021-04-01
• Study First Submitted: 2021-04-13
• Study First Submitted QC: 2021-04-13
• Last Update Submitted: 2021-04-13
• Study First Posted: 2021-04-15
• Last Update Posted: 2021-04-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 182

Inclusion Criteria

Healthy Health Workers - SARS COV-2 PCR (-)

Read More

Exclusion Criteria

Health Workers - SARS COV-2 PCR (+) Pregnancy Autoimmune diseases Received immunosuppressive therapy

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
SARS Cov_2 Incidence of Healthy Health Workers	Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2	-

Primary Outcome Measures

Name	Time	Method
Evaluation of IgG Neutralizing Antibodies to SARS-CoV-2 Among Healthcare Workers Who Frequently Encountered COVID-19 patients in Our Hospital	6 months	Determining antibody levels and seroprevalence of healthy healthcare workers

Trial Locations

Locations (1)

Adana Dr. Turgut Noyan Application and Research Center; 🇹🇷 Adana, Turkey